322 related articles for article (PubMed ID: 20154418)
21. Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.
Zaveri NT; Journigan VB; Polgar WE
ACS Chem Neurosci; 2015 Apr; 6(4):646-57. PubMed ID: 25635572
[TBL] [Abstract][Full Text] [Related]
22. The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510).
Varty GB; Lu SX; Morgan CA; Cohen-Williams ME; Hodgson RA; Smith-Torhan A; Zhang H; Fawzi AB; Graziano MP; Ho GD; Matasi J; Tulshian D; Coffin VL; Carey GJ
J Pharmacol Exp Ther; 2008 Aug; 326(2):672-82. PubMed ID: 18492950
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological characterization of nociceptin/orphanin FQ receptors, a novel opioid receptor family, in the midbrain periaqueductal gray.
Chiou LC; Fan SH; Chuang KC; Liao YY; Lee SZ
Ann N Y Acad Sci; 2004 Oct; 1025():398-403. PubMed ID: 15542742
[TBL] [Abstract][Full Text] [Related]
24. UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPgamma(35)S binding studies.
McDonald J; Calo G; Guerrini R; Lambert DG
Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb; 367(2):183-7. PubMed ID: 12595960
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24.
Fischetti C; Camarda V; Rizzi A; Pelà M; Trapella C; Guerrini R; McDonald J; Lambert DG; Salvadori S; Regoli D; Calo' G
Eur J Pharmacol; 2009 Jul; 614(1-3):50-7. PubMed ID: 19445927
[TBL] [Abstract][Full Text] [Related]
26. Binding of GTPgamma[35S] is regulated by GDP and receptor activation. Studies with the nociceptin/orphanin FQ receptor.
McDonald J; Lambert DG
Br J Pharmacol; 2010 Mar; 159(6):1286-93. PubMed ID: 20148892
[TBL] [Abstract][Full Text] [Related]
27. Nociceptin/orphanin FQ peptide receptor antagonist JTC-801 reverses pain and anxiety symptoms in a rat model of post-traumatic stress disorder.
Zhang Y; Simpson-Durand CD; Standifer KM
Br J Pharmacol; 2015 Jan; 172(2):571-82. PubMed ID: 24666365
[TBL] [Abstract][Full Text] [Related]
28. Structure activity studies of nociceptin/orphanin FQ(1-13)-NH2 derivatives modified in position 5.
Guerrini R; Marzola E; Trapella C; Pacifico S; Cerlesi MC; Malfacini D; Ferrari F; Bird MF; Lambert DG; Salvadori S; Calo G
Bioorg Med Chem; 2015 Apr; 23(7):1515-20. PubMed ID: 25716007
[TBL] [Abstract][Full Text] [Related]
29. In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations.
Ferrari F; Cerlesi MC; Malfacini D; Asth L; Gavioli EC; Journigan BV; Kamakolanu UG; Meyer ME; Yasuda D; Polgar WE; Rizzi A; Guerrini R; Ruzza C; Zaveri NT; Calo G
Eur J Pharmacol; 2016 Dec; 793():1-13. PubMed ID: 27780725
[TBL] [Abstract][Full Text] [Related]
30. [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.
Calo G; Rizzi A; Rizzi D; Bigoni R; Guerrini R; Marzola G; Marti M; McDonald J; Morari M; Lambert DG; Salvadori S; Regoli D
Br J Pharmacol; 2002 May; 136(2):303-11. PubMed ID: 12010780
[TBL] [Abstract][Full Text] [Related]
31. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic.
Thompson AA; Liu W; Chun E; Katritch V; Wu H; Vardy E; Huang XP; Trapella C; Guerrini R; Calo G; Roth BL; Cherezov V; Stevens RC
Nature; 2012 May; 485(7398):395-9. PubMed ID: 22596163
[TBL] [Abstract][Full Text] [Related]
32. Effects of chronic nociceptin/orphanin FQ exposure on cAMP accumulation and receptor density in Chinese hamster ovary cells expressing human nociceptin/orphanin FQ receptors.
Hashimoto Y; Calo' G; Guerrini R; Smith G; Lambert DG
Eur J Pharmacol; 2002 Aug; 449(1-2):17-22. PubMed ID: 12163101
[TBL] [Abstract][Full Text] [Related]
33. [Nphe(1)]NC(1-13)NH(2) selectively antagonizes nociceptin/orphanin FQ-stimulated G-protein activation in rat brain.
Berger H; Calo' G; Albrecht E; Guerrini R; Bienert M
J Pharmacol Exp Ther; 2000 Aug; 294(2):428-33. PubMed ID: 10900215
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4).
Volta M; Marti M; McDonald J; Molinari S; Camarda V; Pelà M; Trapella C; Morari M
Peptides; 2010 Jun; 31(6):1194-204. PubMed ID: 20307605
[TBL] [Abstract][Full Text] [Related]
35. Structure-activity studies on high affinity NOP-active hexapeptides.
Judd AK; Tuttle DJ; Jones RW; Sanchez A; Polgar W; Berzetei-Gurske I; Toll L
J Pept Res; 2004 Sep; 64(3):87-94. PubMed ID: 15317498
[TBL] [Abstract][Full Text] [Related]
36. Nociceptin/orphanin FQ and opioid receptor-like receptor mRNA expression in dopamine systems.
Norton CS; Neal CR; Kumar S; Akil H; Watson SJ
J Comp Neurol; 2002 Mar; 444(4):358-68. PubMed ID: 11891648
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological characterization of a nociceptin receptor from zebrafish (Danio rerio).
Rivas-Boyero AA; Herrero-Turrión MJ; Gonzalez-Nunez V; Sánchez-Simón FM; Barreto-Valer K; Rodríguez RE
J Mol Endocrinol; 2011 Apr; 46(2):111-23. PubMed ID: 21247980
[TBL] [Abstract][Full Text] [Related]
38. Dysregulation of nociceptin/orphanin FQ activity in the amygdala is linked to excessive alcohol drinking in the rat.
Economidou D; Hansson AC; Weiss F; Terasmaa A; Sommer WH; Cippitelli A; Fedeli A; Martin-Fardon R; Massi M; Ciccocioppo R; Heilig M
Biol Psychiatry; 2008 Aug; 64(3):211-8. PubMed ID: 18367152
[TBL] [Abstract][Full Text] [Related]
39. Assessment of the activity of a novel nociceptin/orphanin FQ analogue at recombinant human nociceptin/orphanin FQ receptors expressed in Chinese hamster ovary cells.
Wright KE; McDonald J; Barnes TA; Rowbotham DJ; Guerrini R; Calo' G; Lambert DG
Neurosci Lett; 2003 Aug; 346(3):145-8. PubMed ID: 12853105
[TBL] [Abstract][Full Text] [Related]
40. The nociceptin/orphanin FQ receptor antagonist UFP-101 reduces microvascular inflammation to lipopolysaccharide in vivo.
Brookes ZL; Stedman EN; Brown NJ; Hebbes CP; Guerrini R; Calo G; Reilly CS; Lambert DG
PLoS One; 2013; 8(9):e74943. PubMed ID: 24086402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
